Adaptive Biotechnologies (ADPT) Current Leases (2020 - 2026)

Adaptive Biotechnologies has disclosed Current Leases across 7 years of filings, most recently posting $8.5 million for Q1 2026.

• Current Leases for Q1 2026 came in at $8.5 million, down 18.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.5 million (down 18.63% YoY), and the FY2025 annual result was $8.9 million, down 12.88% from the prior year.
• Current Leases came in at $8.5 million for Q1 2026 at Adaptive Biotechnologies, down from $8.9 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $10.5 million in Q1 2025 to a low of $8.5 million in Q1 2026.
• The 5-year median for Current Leases is $9.4 million (2023), against an average of $9.4 million.
• Across the five-year window, Current Leases soared 98.35% in 2022 and dropped 18.63% in 2026, its largest moves.
• Adaptive Biotechnologies' Current Leases stood at $9.2 million in 2022, then rose by 1.67% to $9.4 million in 2023, then grew by 9.11% to $10.2 million in 2024, then retreated by 12.88% to $8.9 million in 2025, then dropped by 4.56% to $8.5 million in 2026.
• The last three Current Leases figures came in at $8.5 million (Q1 2026), $8.9 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.